Abstract 544P
Background
Immune checkpoint inhibitors (ICI) have revolutionized the treatment landscape. While programmed death-ligand 1 expression serves as a predictive biomarker, uncovering extra ICI response markers is pivotal. Immune cell transcriptomic analysis is a promising path for identifying such markers. Our study aims to find an ICI response predictor in lung adenocarcinoma patients' peripheral blood mononuclear cells (PBMC) through single-cell RNA sequencing (scRNA-seq).
Methods
We prospectively collected PBMC from 38 patients with stage IV lung adenocarcinoma, both before (0-7 days) and after (1-3 weeks) treatment with anti-PD(L)-1 therapy. Among the patients, 17 achieved a partial response, 4 had stable disease, and 17 experienced disease progression. Patients with a partial response or stable disease were classified as responders, while those with disease progression were classified as non-responders. We performed scRNA-seq on PBMC to unravel the molecular landscape.
Results
Subgroup analysis of NKT cells in pre-treated state revealed upregulated RNA expression related to activator protein 1 (AP-1) signals in NK cell subtypes (CD56lowCD16int NK cell, CCL4 NK cell, PTGDS NK cell) in responders. CD56 high CD16 low expressing NK cells were increased in responder after treatment with ICI. Additionally, we found an increased proportion of monocytes with high CXCL10 expression in the responder group. Signals associated with chemokine ligands and interferon-inducible proteins were upregulated in monocyte subtypes prior to ICI treatment.
Conclusions
Our scRNA-seq analysis of PBMC from lung adenocarcinoma patients provided valuable insights into the immune landscape. Upregulation of AP-1 signals in NK cells and chemokine ligand expression, as well as interferon-inducible signals in monocytes, were observed in responders prior to ICI treatment. Moreover, the expansion of monocytes with high CXCL10 expression in the responder group suggests the potential involvement of these circulating immune cell populations in the anti-tumor immune response. These findings contribute to our understanding of ICI response and offer promise for the future development of predictive biomarkers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
592P - Treatment patterns and outcomes in patients with advanced non-small cell lung cancer with MET exon 14 skipping alterations in China
Presenter: Hanxiao Chen
Session: Poster Display
Resources:
Abstract
593P - MET TKIs in Asian patients (pts) with MET exon 14 skipping NSCLC: A matching-adjusted indirect comparison (MAIC)
Presenter: E-e Ke
Session: Poster Display
Resources:
Abstract
594P - The treatment pattern and clinical outcome in NSCLC patients with MET alteration: A retrospective real-world analysis in China
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
595P - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
Presenter: Koichi Goto
Session: Poster Display
Resources:
Abstract
596P - Repotrectinib in patients (pts) from Asia and China with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC): Results from the phase I/II TRIDENT-1 trial
Presenter: Ross Soo
Session: Poster Display
Resources:
Abstract
597TiP - A phase I/II study to evaluate the safety and anti-tumor activity of JIN-A02 in patients with EGFR TKI-refractory, EGFR-mutant advanced NSCLC
Presenter: Sun Min Lim
Session: Poster Display
Resources:
Abstract
598TiP - Exploration of aumolertinib in first-line treatment for advanced non-small cell lung cancer patients of performance status 3 with EGFR mutations (19del and L858R)
Presenter: Haiyi Deng
Session: Poster Display
Resources:
Abstract
599TiP - A prospective study of savolitinib plus docetaxel in pretreated EGFR/ALK/ROS1/METex14m-wildtype advanced NSCLC patients with MET overexpression (FirstMET)
Presenter: Shuting Zhan
Session: Poster Display
Resources:
Abstract
600TiP - Phase III study of telisotuzumab vedotin (Teliso-V) vs docetaxel in pretreated c-Met overexpressing EGFR wildtype (WT) non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC)
Presenter: Junko Tanizaki
Session: Poster Display
Resources:
Abstract
601P - Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158
Presenter: Xiaohua Wu
Session: Poster Display
Resources:
Abstract